Angiotensin Converting Enzyme 2 News and Research

RSS

Does SARS-CoV-2's ability to infect humans stem from its evolutionary past?

Study challenges the hypothesis of genetic recombination in SARS-CoV-2's evolution, suggesting its ancestral virus already possessed human-infecting traits, based on analyses of over 100 viral genomes.

7 Jan 2024

IFNγ identified as crucial for reducing pulmonary viral loads in COVID-19, new research shows

The role of type-2 interferon (IFNγ) in antiviral immunity.

14 Dec 2023

New SARS-CoV-2 variant JN.1 shows increased transmissibility and immune resistance

A Japanese study published in BioRxiv explores the virological characteristics of the SARS-CoV-2 JN.1 variant, finding it has a higher effective reproductive number and stronger resistance to immunity from other variants, potentially due to the L455S spike protein mutation.

11 Dec 2023

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

The safety, efficacy, and immunogenicity of a mRNA-based vaccine.

5 Dec 2023

Omicron infection linked to brain structure changes in men, study finds

Study reveals that men infected with the SARS-CoV-2 Omicron variant experience changes in brain structure, including reduced gray matter thickness and subcortical nuclear volume. These findings, based on MRI data and clinical symptoms, highlight the neurological impact of Omicron infection, contributing to our understanding of COVID-19's effects on the brain.

4 Dec 2023

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Study discovers that coffee, especially its bioactive compounds like chlorogenic acids, can inhibit SARS-CoV-2 entry and reduce ACE2 and TMPRSS2 levels, indicating that coffee intake might be a potential dietary strategy for COVID-19 prevention.

16 Nov 2023

Senolytics show promise in combating brain aging and COVID-19 neuropathology

Study reveals that senolytics can reduce aging in human brain organoids and mitigate COVID-19 neuropathology, suggesting their potential as a therapeutic strategy against brain aging and coronavirus-related neurological complications.

15 Nov 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

24 Oct 2023

Community immunity: Steering the evolutionary course of SARS-CoV-2

Researchers in Germany have developed a comprehensive fitness model that forecasts the evolution of SARS-CoV-2 by integrating genetic, epidemiological, and immunological data. The study emphasizes the role of population immunity in shaping viral mutations and provides valuable insights into the emergence of new variants.

24 Oct 2023

Is COVID-19 a risk factor for Alzheimer's disease?

The study explores the interconnected risks between COVID-19 and Alzheimer's Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.

23 Oct 2023

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.

22 Oct 2023

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

20 Oct 2023

Low serotonin levels observed in long COVID and other viral infections

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

20 Oct 2023

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

The efficacy of tea and its catechins in deactivating the Omicron subvariant.

5 Oct 2023

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA's multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

14 Sep 2023

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers identify a new SARS-CoV-2 variant, BA.2.86, with enhanced ability to evade immunity but lower infectivity compared to current variants. The study highlights the need for global monitoring due to its potential to become a predominant strain if it gains infectivity through mutations.

6 Sep 2023

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.